A Phase 1/2, Multicenter, Open-Label, Multicohort Study Evaluating the Safety and Efficacy of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors
Coherus Oncology, Inc.
Summary
The primary purpose of this study is to evaluate the safety and tolerability of tagmokitug in combination with other therapies.
Eligibility
- Age range
- 18+ years
- Sex
- Male
- Healthy volunteers
- No
Key Inclusion Criteria: * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1. * Resolved acute effects of any prior therapy to baseline severity or Grade 1 in accordance with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0, except for adverse events (AEs) not constituting a safety risk per Investigator judgment. mCRPC: * Histologically confirmed adenocarcinoma of the prostate. Adenocarcinoma with focal small cell or neuroendocrine (NE) features based on immunohistochemistry (IHC) alone is permitted. However, small cell carci…
Interventions
- DrugTagmokitug
Specified dose on specified days.
- DrugPasritamig
Specified dose on specified days.
Location
- Fred Hutchinson Cancer CenterSeattle, Washington